Literature DB >> 16210370

The Leu34Phe ProCART mutation leads to cocaine- and amphetamine-regulated transcript (CART) deficiency: a possible cause for obesity in humans.

Tulin Yanik1, Geraldina Dominguez, Michael J Kuhar, Emanuele M Del Giudice, Y Peng Loh.   

Abstract

Cocaine- and amphetamine-regulated transcript (CART) is an anorexigenic neuropeptide synthesized in the hypothalamus. A Leu34Phe missense mutation in proCART has been found in an obese family in humans. Here we show that humans bearing the Leu34Phe mutation in proCART have severely diminished levels of bioactive CART, but elevated amounts of partially processed proCART in their serum. Expression of wild-type proCART in AtT-20 cells showed that it was sorted to the regulated secretory pathway, a necessity for proper processing to bioactive CART. However, expressed Leu34Phe proCART was missorted, poorly processed, and secreted constitutively. The defective intracellular sorting of Leu34Phe proCART would account for the reduced levels of bioactive CART in affected humans. These results suggest that the obesity observed in humans bearing the Leu34Phe mutation could be due to a putative deficiency in hypothalamic bioactive CART.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210370     DOI: 10.1210/en.2005-0812

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

Review 1.  New roles of carboxypeptidase E in endocrine and neural function and cancer.

Authors:  Niamh X Cawley; William C Wetsel; Saravana R K Murthy; Joshua J Park; Karel Pacak; Y Peng Loh
Journal:  Endocr Rev       Date:  2012-03-07       Impact factor: 19.871

Review 2.  CART peptides: regulators of body weight, reward and other functions.

Authors:  G Rogge; D Jones; G W Hubert; Y Lin; M J Kuhar
Journal:  Nat Rev Neurosci       Date:  2008-10       Impact factor: 34.870

3.  Intra-accumbal administration of shRNAs against CART peptides cause increases in body weight and cocaine-induced locomotor activity in rats.

Authors:  M O Job; J Licata; G W Hubert; M J Kuhar
Journal:  Brain Res       Date:  2012-09-11       Impact factor: 3.252

4.  Obese carboxypeptidase E knockout mice exhibit multiple defects in peptide hormone processing contributing to low bone mineral density.

Authors:  Niamh X Cawley; Tulin Yanik; Alicja Woronowicz; Weizhong Chang; Joan C Marini; Y Peng Loh
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-05-11       Impact factor: 4.310

Review 5.  Obesity and lipodystrophy--where do the circles intersect?

Authors:  Farid F Chehab
Journal:  Endocrinology       Date:  2008-01-17       Impact factor: 4.736

Review 6.  Current and emerging therapeutic targets for Parkinson's disease.

Authors:  Tanvi Pingale; Girdhari Lal Gupta
Journal:  Metab Brain Dis       Date:  2020-10-22       Impact factor: 3.584

7.  Neurotransmitter CART as a New Therapeutic Candidate for Parkinson's Disease.

Authors:  Peizhong Mao; Charles K Meshul; Philippe Thuillier; P Hemachandra Reddy
Journal:  Pharmaceuticals (Basel)       Date:  2013

8.  Elevated cocaine- and amphetamine-regulated transcript immunoreactivity in the circulation of patients with neuroendocrine malignancy.

Authors:  Paul Bech; Virginia Winstanley; Kevin G Murphy; Amir H Sam; Karim Meeran; Mohammad A Ghatei; Stephen R Bloom
Journal:  J Clin Endocrinol Metab       Date:  2008-01-22       Impact factor: 5.958

9.  Signaling in rat brainstem via Gpr160 is required for the anorexigenic and antidipsogenic actions of cocaine- and amphetamine-regulated transcript peptide.

Authors:  Christopher J Haddock; Gislaine Almeida-Pereira; Lauren M Stein; Matthew R Hayes; Grant R Kolar; Willis K Samson; Gina L C Yosten
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-11-18       Impact factor: 3.619

10.  An amphipathic alpha-helix in the prodomain of cocaine and amphetamine regulated transcript peptide precursor serves as its sorting signal to the regulated secretory pathway.

Authors:  Elías H Blanco; Carlos F Lagos; María Estela Andrés; Katia Gysling
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.